Hi! My name is <NAME>, and I’m calling from <PART OF STATE>.
I’m calling to urge you to co-sponsor H.R. 1046, Rep. Doggett’s Medicare Negotiation and Competitive Licensing Act because it will bring down our obscenely high drug prices while protecting patients’ access to critical medicines.
We need to give Medicare the ability to negotiate drug prices, but that new power must be paired with the appropriate leverage so that drug companies can’t continue gouging patients. Rep. Doggett’s bill includes a provision that allows the government to issue a competitive license if drug companies refuse to come to the table.
This is important because it means that efforts to lower prices will put drug companies’ monopolies in the crosshairs—not patient’s access to medicine.
Will <MoC> commit to co-sponsoring H.R. 1046, the Medicare Negotiation and Competitive Licensing Act?
H.R. 1046, the Medicare Negotiation and Competitive Licensing Act
Call your Member of Congress and tell them to co-sponsor ! Give Medicare the power it needs to effectively negotiate with drug companies and bring drug prices down!
Prescription drug prices are substantially higher in the United States than in other high-income countries, and as a result Americans spend more on prescription drugs than residents of other countries. Despite this, the government is not allowed to use its position as the largest purchaser of prescription drugs in the country (through Medicare Part D) to bargain for lower prices for patients. House Democrats have pledged to work on lowering prescription drug prices now that they are in the majority, including by allowing Medicare to negotiate prices, but it isn’t yet clear which bill they will bring to the floor to accomplish this.
Rep. Lloyd Doggett (D-TX) has introduced the Medicare Negotiation and Competitive Licensing Act (H.R. 1046) to give Medicare the power it needs to effectively negotiate with drug companies and bring drug prices down. Call your Representative (MoC) and tell them: co-sponsor H.R. 1046, the Medicare Negotiation and Competitive Licensing Act!
In this resource, we’ll tell you more about how H.R. 1046 will bring drug prices down, and provide you with the tools you need to tell your MoC to become a co-sponsor.
What would the bill do?
Almost 9 in 10 Americans support making it easier for generic drugs to come to market, and a similar number support allowing the government to negotiate with drug companies to get a lower prescription drug price for people with Medicare. Rep. Doggett’s bill lifts the restrictions that currently prevent Medicare from negotiating with drug companies, but just as importantly it would give Medicare the leverage it needs to negotiate effectively without putting patients at risk.
Here’s how it would work:
Drug companies like to argue that introducing competitive licensing would hurt their bottom line or reduce innovation, but that just isn’t true. H.R. 1046 includes a provision that ensures they receive reasonable compensation in the event that a license is issued for one of their drugs, meaning their investment won’t be completely lost—just their ability to exploit it to extract maximum profit from the patients who take their medicine.
It also bears mentioning that public funding plays a major role in the research and development of new drugs. Of the 210 drugs approved by the FDA from 2010-2016, every single one was associated with NIH-funded research. If taxpayers are helping to fund the research that drug companies use to generate new products, drug companies should not be able to turn around and gouge those same people with high prices once the drugs reach the market.
Call your MoC now and tell them to co-sponsor H.R. 1046, the Medicare Negotiation and Competitive Licensing Act!